Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 1:13:1044683.
doi: 10.3389/fphar.2022.1044683. eCollection 2022.

β-lactam precision dosing in critically ill children: Current state and knowledge gaps

Sonya Tang Girdwood  1   2   3 , Kathryn Pavia  4 , Kelli Paice  4 , H Rhodes Hambrick  5 , Jennifer Kaplan  3   4 , Alexander A Vinks  1   3
Affiliations
Review

β-lactam precision dosing in critically ill children: Current state and knowledge gaps

Sonya Tang Girdwood et al. Front Pharmacol. .

Abstract

There has been emerging interest in implementing therapeutic drug monitoring and model-informed precision dosing of β-lactam antibiotics in critically ill patients, including children. Despite a position paper endorsed by multiple international societies that support these efforts in critically ill adults, implementation of β-lactam precision dosing has not been widely adopted. In this review, we highlight what is known about β-lactam antibiotic pharmacokinetics and pharmacodynamics in critically ill children. We also define the knowledge gaps that present barriers to acceptance and implementation of precision dosing of β-lactam antibiotics in critically ill children: a lack of consensus on which subpopulations would benefit most from precision dosing and the uncertainty of how precision dosing changes outcomes. We conclude with opportunities for further research to close these knowledge gaps.

Keywords: beta-lactam antibiotics; critically ill; pediatrics; population pharmacokinetic models; precision dosing.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Abdul-Aziz M. H., Alffenaar J. C., Bassetti M., Bracht H., Dimopoulos G., Marriott D., et al. (2020). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 46 (6), 1127–1153. 10.1007/s00134-020-06050-1 - DOI - PMC - PubMed
    1. Abdul-Aziz M. H., Sulaiman H., Mat-Nor M. B., Rai V., Wong K. K., Hasan M. S., et al. (2016). Beta-lactam infusion in severe sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 42 (10), 1535–1545. 10.1007/s00134-015-4188-0 - DOI - PubMed
    1. Abdulla A., Dijkstra A., Hunfeld N. G. M., Endeman H., Bahmany S., Ewoldt T. M. J., et al. (2020). Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT). Crit. Care 24 (1), 558. 10.1186/s13054-020-03272-z - DOI - PMC - PubMed
    1. Al-Shaer M. H., Neely M. N., Liu J., Cherabuddi K., Venugopalan V., Rhodes N. J., et al. (2020). Population pharmacokinetics and target attainment of cefepime in critically ill patients and guidance for initial dosing. Antimicrob. Agents Chemother. 64 (9), 007455-20. 10.1128/AAC.00745-20 - DOI - PMC - PubMed
    1. Al-Shaer M. H., Philpott C. D., Droege C. A., Courter J. D., Healy D. P., Droege M. E., et al. (2021). Cefepime population pharmacokinetics and target attainment in critically ill patients on continuous renal replacement therapy. Antimicrob. Agents Chemother. 65 (6), 001444-21. 10.1128/AAC.00144-21 - DOI - PMC - PubMed

LinkOut - more resources